#BEGIN_DRUGCARD DB00522

# AHFS_Codes:
Not Available

# ATC_Codes:
V04CK03

# Absorption:
Not Available

# Biotransformation:
Primarily hepatic. Enzymatic activity capable of hydrolyzing bentiromide has also been found in normal small intestine.

# Brand_Mixtures:
Not Available

# Brand_Names:
Chymex

# CAS_Registry_Number:
37106-97-1

# ChEBI_ID:
31263

# Chemical_Formula:
C23H20N2O5

# Chemical_IUPAC_Name:
4-[(2S)-3-(4-hydroxyphenyl)-2-(phenylformamido)propanamido]benzoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada (It was withdrawn in the US in October 1996).

# Dosage_Forms:
Not Available

# Drug_Category:
Diagnostic aids
Indicators and Reagents

# Drug_Interactions:
Not Available

# Drug_Reference:
6371722	Toskes PP: The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Bentiromide

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1

# InChI_Key:
InChIKey=SPPTWHFVYKCNNK-FQEVSTJZSA-N

# Indication:
Used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01346

# LIMS_Drug_ID:
522

# Mechanism_Of_Action:
Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. By determining the output of unchanged bentiromide in the urine following oral administration, it is possible to determine the sufficiency of pancreatic activity.

# Melting_Point:
241 Â°C

# Molecular_Weight_Avg:
404.4153

# Molecular_Weight_Mono:
404.13722176

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164750572

# Pharmacology:
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of <i>p</i>-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada.

# Predicted_LogP_Hydrophobicity:
2.99

# Predicted_LogS:
-5

# Predicted_Water_Solubility:
4.12e-03 g/l

# Primary_Accession_No:
DB00522

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00818

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
BTPABA
Bentiromide [USAN:BAN:INN:JAN]
Bentiromido [INN-Spanish]
Bentiromidum [INN-Latin]
PFT

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include shortness of breath and troubled breathing.

# Update_Date:
2013-02-08 16:19:25 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Bentiromide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
12641496	Chowdhury RS, Forsmark CE: Review article: Pancreatic function testing. Aliment Pharmacol Ther. 2003 Mar 15;17(6):733-50.
3258344	Bujanover Y, Harel A, Geter R, Blau H, Yahav J, Spirer Z: The development of the chymotryptic activity during postnatal life using the bentiromide test. Int J Pancreatol. 1988 Jan-Feb;3(1):53-8.
6371722	Toskes PP: The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
HPN

# Drug_Target_1_GenBank_ID_Gene:
M18930

# Drug_Target_1_GenBank_ID_Protein:
306886

# Drug_Target_1_GeneCard_ID:
HPN

# Drug_Target_1_Gene_Name:
HPN

# Drug_Target_1_Gene_Sequence:
>1254 bp
ATGGCGCAGAAGGAGGGTGGCCGGACTGTGCCATGCTGCTCCAGACCCAAGGTGGCAGCT
CTCACTGCGGGGACCCTGCTACTTCTGACAGCCATCGGGGCGGCATCCTGGGCCATTGTG
GCTGTTCTCCTCAGGAGTGACCAGGAGCCGCTGTACCCAGTGCAGGTCAGCTCTGCGGAC
GCTCGGCTCATGGTCTTTGACAAGACGGAAGGGACGTGGCGGCTGCTGTGCTCCTCGCGC
TCCAACGCCAGGGTAGCCGGACTCAGCTGCGAGGAGATGGGCTTCCTCAGGGCACTGACC
CACTCCGAGCTGGACGTGCGAACGGCGGGCGCCAATGGCACGTCGGGCTTCTTCTGTGTG
GACGAGGGGAGGCTGCCCCACACCCAGAGGCTGCTGGAGGTCATCTCCGTGTGTGATTGC
CCCAGAGGCCGTTTCTTGGCCGCCATCTGCCAAGACTGTGGCCGCAGGAAGCTGCCCGTG
GACCGCATCGTGGGAGGCCGGGACACCAGCTTGGGCCGGTGGCCGTGGCAAGTCAGCCTT
CGCTATGATGGAGCACACCTCTGTGGGGGATCCCTGCTCTCCGGGGACTGGGTGCTGACA
GCCGCCCACTGCTTCCCGGAGCGGAACCGGGTCCTGTCCCGATGGCGAGTGTTTGCCGGT
GCCGTGGCCCAGGCCTCTCCCCACGGTCTGCAGCTGGGGGTGCAGGCTGTGGTCTACCAC
GGGGGCTATCTTCCCTTTCGGGACCCCAACAGCGAGGAGAACAGCAACGATATTGCCCTG
GTCCACCTCTCCAGTCCCCTGCCCCTCACAGAATACATCCAGCCTGTGTGCCTCCCAGCT
GCCGGCCAGGCCCTGGTGGATGGCAAGATCTGTACCGTGACGGGCTGGGGCAACACGCAG
TACTATGGCCAACAGGCCGGGGTACTCCAGGAGGCTCGAGTCCCCATAATCAGCAATGAT
GTCTGCAATGGCGCTGACTTCTATGGAAACCAGATCAAGCCCAAGATGTTCTGTGCTGGC
TACCCCGAGGGTGGCATTGATGCCTGCCAGGGCGACAGCGGTGGTCCCTTTGTGTGTGAG
GACAGCATCTCTCGGACGCCACGTTGGCGGCTGTGTGGCATTGTGAGTTGGGGCACTGGC
TGTGCCCTGGCCCAGAAGCCAGGCGTCTACACCAAAGTCAGTGACTTCCGGGAGTGGATC
TTCCAGGCCATAAAGACTCACTCCGAAGCCAGCGGCATGGTGACCCAGCTCTGA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
1885621	Tsuji A, Torres-Rosado A, Arai T, Le Beau MM, Lemons RS, Chou SH, Kurachi K: Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. J Biol Chem. 1991 Sep 5;266(25):16948-53.
2835076	Leytus SP, Loeb KR, Hagen FS, Kurachi K, Davie EW: A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry. 1988 Feb 9;27(3):1067-74.
8346233	Torres-Rosado A, O'Shea KS, Tsuji A, Chou SH, Kurachi K: Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7181-5.

# Drug_Target_1_HGNC_ID:
HGNC:5155

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3851

# Drug_Target_1_Locus:
19q11-q13.2

# Drug_Target_1_Molecular_Weight:
45012

# Drug_Target_1_Name:
Serine protease hepsin

# Drug_Target_1_Number_of_Residues:
417

# Drug_Target_1_PDB_ID:
1Z8G

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00089	Trypsin
PF09272	Hepsin-SRCR

# Drug_Target_1_Protein_Sequence:
>Serine protease hepsin
MAQKEGGRTVPCCSRPKVAALTAGTLLLLTAIGAASWAIVAVLLRSDQEPLYPVQVSSAD
ARLMVFDKTEGTWRLLCSSRSNARVAGLSCEEMGFLRALTHSELDVRTAGANGTSGFFCV
DEGRLPHTQRLLEVISVCDCPRGRFLAAICQDCGRRKLPVDRIVGGRDTSLGRWPWQVSL
RYDGAHLCGGSLLSGDWVLTAAHCFPERNRVLSRWRVFAGAVAQASPHGLQLGVQAVVYH
GGYLPFRDPNSEENSNDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGKICTVTGWGNTQ
YYGQQAGVLQEARVPIISNDVCNGADFYGNQIKPKMFCAGYPEGGIDACQGDSGGPFVCE
DSISRTPRWRLCGIVSWGTGCALAQKPGVYTKVSDFREWIFQAIKTHSEASGMVTQL

# Drug_Target_1_Reaction:
Cleavage after basic amino-acid residues, with Arg strongly preferred to Lys

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Plays an essential role in cell growth and maintenance of cell morphology

# Drug_Target_1_SwissProt_ID:
P05981

# Drug_Target_1_SwissProt_Name:
HEPS_HUMAN

# Drug_Target_1_Synonyms:
EC 3.4.21.106
Transmembrane protease, serine 1

# Drug_Target_1_Theoretical_pI:
7.66

# Drug_Target_1_Transmembrane_Regions:
24-44

#END_DRUGCARD DB00522
